Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin ...

Physical therapy can help maintain muscle ... MedlinePlus. DMD gene. MedlinePlus. Duchenne muscular dystrophy. National Human Genome Research Institute. About Duchenne muscular dystrophy.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

a gene therapy aimed at treating Duchenne muscular dystrophy. Data from the first three participants, gathered 90 days post-treatment, indicated an average microdystrophin expression of 110% along ...